Curcumin encapsulation in functional PLGA nanoparticles: A promising strategy for cancer therapies

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

“…EVs are divided into four subgroups: exosomes (30–150 nm in diameter), microvesicles (100–1000 nm in diameter), apoptotic bodies (100–5000 nm in diameter), and oncosomes (1–10 μm in diameter). TEVs are promising tumor vaccines due to the existence of immunogenic molecules, such as nucleic acids, TAAs, and damage-associated molecular patterns, which can stimulate the maturation of immune cells to initiate an antitumor response [ [127] , [128] , [129] ]. Current studies on the application of TEVs in vaccines have mainly focused on exosomes and microvesicles.…”

“…The application of inorganic nanoparticles is occasionally constrained by concerns regarding their potential toxicity. In contrast, organic polymeric materials such as PLGA have been approved by the FDA as safe for clinical applications [ 127 ], and they are commonly used as biomaterials for drug delivery because of their good biocompatibility, degradability, resistance to degradation of carried substances, and slow release [ 185 , 193 , 194 ]. In tumor cell membrane-derived nanovaccines, PLGA loaded with immune adjuvant allows stable delivery to the target site and activates the immune response.…”

Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection

“…715,716 Various nanocarriers have been utilized to load curcumin for longer blood circulation half-life and better tissue distribution. [717][718][719][720][721] For example, Xie et al modified bamboo charcoal NPs (BCNPs) with D-a-tocopherol polyethylene glycol succinate (TPGS) and then loaded curcumin into the NPs (TPGS-BCNPs@curcumin) for both radiosensitization and radioprotection. 550 The TPGS-BCNPs exhibited good biocompatibility and high tumor accumulation.…”

Mechanisms Underlying Curcumin-Induced Neuroprotection in Cerebral Ischemia

“…It is challenging to dissolve, extract, and absorb curcumin, resulting in low bioavailability and limited clinical applications ( Esatbeyoglu et al, 2012 ; Kotha and Luthria, 2019 ). In recent years, numerous drug delivery systems using liposomes, nanoparticles, and microemulsion as carriers have been successfully developed, which significantly increased the solubility, stability, and safety of curcumin, and greatly improved its biological activity in treating or preventing diseases, showing great promise for clinical application ( Aggarwal and Sung, 2009 ; Mahmood et al, 2015 ; Abd El-Hack et al, 2021 ; Jabczyk et al, 2021 ; Feltrin et al, 2022 ).…”